By Sungmin Kim, Biospectator | Published: October 14, 2025, 08:44 KST | Updated: October 14, 2025, 08:44 KST

IMBiologics, which is developing pipelines for autoimmune diseases and immuno-oncology therapeutics, has been accelerating its R&D efforts. Since its establishment in 2020, the company has raised a total of 79.2 billion KRW in cumulative funding. In August, it passed the technology evaluation required for a special listing on KOSDAQ.

▲Kyong-sik Ha, CEO of IMBiologics

IMBiologics announced on the 14th that it has successfully closed a pre-IPO funding round worth 42.2 billion KRW. With this latest round, the total funds raised by the company since its founding in August 2020 now amount to 79.2 billion KRW. Previously, the company secured 4 billion KRW in seed funding in 2021, followed by 13 billion KRW in Series A, and 20 billion KRW in Series B funding in 2023.

In August of this year, IMBiologics passed the technology evaluation for a special KOSDAQ listing and is targeting an IPO in the first half of next year.

Participating follow-on investors in this round include Atinum Investment, Partners Investment, CJ Investment, K2 Investment Partners, Prodigy Investment, Shinhan Venture Investment, Wooshin Venture Investment, Timefolio Capital/Shinhan Capital, LSK Investment, and Kingo Investment Partners. New investors include Korea Development Bank (KDB), Quad Asset Management, DS Asset Management/DS Investment Partners, AJU IB, Korea Investment & Securities, and Shinhan Investment Corp.

IMBiologics plans to use the newly secured funds to develop new drug programs for autoimmune diseases and immuno-oncology therapies, and to form global partnerships. In August, the company entered into a joint development partnership with Chinese biotech firm GeneQuantum for multivalent antibody-drug conjugates (ADCs). This collaboration combines IMBiologics' multivalent antibody backbone platform technology, ePENDY (enhanced/engineered PENtamer boDY), with GeneQuantum’s payload and linker technologies.

CEO Kyung-sik Ha of IMBiologics stated, “In addition to the pipelines that have already been licensed out, we plan to expand our core pipeline currently under research, accelerate development, and deliver new business results. We are committed to growing into a global biotech company that launches innovative new drugs in the fields of autoimmune disease and immuno-oncology.”

Sungmin Kim | sungmin.kim@bios.co.kr

Copyright © Biospectator. All rights reserved. Reproduction, redistribution, and use for AI training are prohibited.